FENC Stock — Fennec Pharmaceuticals Inc

Fennec Pharmaceuticals Inc (FENC)

Updated October 16, 2026.

FENC is a Stock. Total return is -91.2% over the past 21.9 years, 953.2 points behind SPY at 862.0%.

Fennec Pharmaceuticals is a commercial-stage biopharmaceutical company developing and selling PEDMARK, a formulation of sodium thiosulfate designed to prevent hearing loss in pediatric cancer patients receiving cisplatin-based chemotherapy. The company markets its product through pediatric oncology specialists and medical science liaisons, and maintains clinical collaboration agreements to evaluate the drug's use in adolescent and adult patient populations. Fennec does not currently distribute to shareholders.

FENC performance versus SPY

Price and return data through 2026-10-16.

Total return is -91.2% over the past 21.9 years, 953.2 points behind SPY at 862.0%. Over the past year its total return — price change plus distributions reinvested — is 15.5%. Its deepest 1-year drawdown was 35.8%.

FENC key facts

Asset type

Stock

Asset class

Equity

Inception date

11/12/2004

Distribution frequency

None

Last close

$9.98 (as of 2026-10-16)

Market cap

$349,970,247

Average volume

129970.0

Beta

1.23

Payout ratio

0.0%

Forward P/E

10.5708

EPS

$-0.12

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

FENC risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 35.8%.

Who may consider FENC — and who may not

It is a weaker fit for investors who need monthly cash flow (FENC does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on FENC

• All tickers starting with F

Tagged: Healthcare.

Frequently asked questions